» Articles » PMID: 33433576

Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017

Overview
Journal JAMA
Specialty General Medicine
Date 2021 Jan 12
PMID 33433576
Citations 163
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Substantial increases in both neonatal abstinence syndrome (NAS) and maternal opioid use disorder have been observed through 2014.

Objective: To examine national and state variation in NAS and maternal opioid-related diagnoses (MOD) rates in 2017 and to describe national and state changes since 2010 in the US, which included expanded MOD codes (opioid use disorder plus long-term and unspecified use) implemented in International Classification of Disease, 10th Revision, Clinical Modification.

Design, Setting, And Participants: Repeated cross-sectional analysis of the 2010 to 2017 Healthcare Cost and Utilization Project's National Inpatient Sample and State Inpatient Databases, an all-payer compendium of hospital discharge records from community nonrehabilitation hospitals in 47 states and the District of Columbia.

Exposures: State and year.

Main Outcomes And Measures: NAS rate per 1000 birth hospitalizations and MOD rate per 1000 delivery hospitalizations.

Results: In 2017, there were 751 037 birth hospitalizations and 748 239 delivery hospitalizations in the national sample; 5375 newborns had NAS and 6065 women had MOD documented in the discharge record. Mean gestational age was 38.4 weeks and mean maternal age was 28.8 years. From 2010 to 2017, the estimated NAS rate significantly increased by 3.3 per 1000 birth hospitalizations (95% CI, 2.5-4.1), from 4.0 (95% CI, 3.3-4.7) to 7.3 (95% CI, 6.8-7.7). The estimated MOD rate significantly increased by 4.6 per 1000 delivery hospitalizations (95% CI, 3.9-5.4), from 3.5 (95% CI, 3.0-4.1) to 8.2 (95% CI, 7.7-8.7). Larger increases for MOD vs NAS rates occurred with new International Classification of Disease, 10th Revision, Clinical Modification codes in 2016. From a census of 47 state databases in 2017, NAS rates ranged from 1.3 per 1000 birth hospitalizations in Nebraska to 53.5 per 1000 birth hospitalizations in West Virginia, with Maine (31.4), Vermont (29.4), Delaware (24.2), and Kentucky (23.9) also exceeding 20 per 1000 birth hospitalizations, while MOD rates ranged from 1.7 per 1000 delivery hospitalizations in Nebraska to 47.3 per 1000 delivery hospitalizations in Vermont, with West Virginia (40.1), Maine (37.8), Delaware (24.3), and Kentucky (23.4) also exceeding 20 per 1000 delivery hospitalizations. From 2010 to 2017, NAS and MOD rates increased significantly for all states except Nebraska and Vermont, which only had MOD increases.

Conclusions And Relevance: In the US from 2010 to 2017, estimated rates of NAS and MOD significantly increased nationally and for the majority of states, with notable state-level variation.

Citing Articles

Prevalence and Treatment of Maternal Substance Use Disorder in Child Welfare.

Goldstein E, Font S JAMA Health Forum. 2025; 6(3):e250054.

PMID: 40053337 PMC: 11889472. DOI: 10.1001/jamahealthforum.2025.0054.


Prenatal Opioid Use Disorder and the Risk of Congenital Anomalies in Offspring: A Population-Based Study.

Ramage K, Yee J, Srugo S, Little J, Liu S Birth Defects Res. 2025; 117(2):e2456.

PMID: 39976348 PMC: 11841020. DOI: 10.1002/bdr2.2456.


Disrupted maternal behavior in morphine-dependent pregnant rats and anhedonia in their offspring.

Searles C, Vogt M, Adedokun I, Murphy A Neuropharmacology. 2025; 270:110372.

PMID: 39971232 PMC: 11885001. DOI: 10.1016/j.neuropharm.2025.110372.


Usability and Acceptability of a Pregnancy App for Substance Use Screening and Education: A Mixed Methods Exploratory Pilot Study.

Fitzgerald H, Frank M, Kasula K, Krans E, Krishnamurti T JMIR Pediatr Parent. 2025; 8:e60038.

PMID: 39946420 PMC: 11841748. DOI: 10.2196/60038.


Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.

Lam K, Mondick J, Peltz G, Wu M, Kraft W Clin Transl Sci. 2025; 18(2):e70147.

PMID: 39930952 PMC: 11811511. DOI: 10.1111/cts.70147.


References
1.
Haight S, Ko J, Tong V, Bohm M, Callaghan W . Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep. 2018; 67(31):845-849. PMC: 6089335. DOI: 10.15585/mmwr.mm6731a1. View

2.
Admon L, Bart G, Kozhimannil K, Richardson C, Dalton V, Winkelman T . Amphetamine- and Opioid-Affected Births: Incidence, Outcomes, and Costs, United States, 2004-2015. Am J Public Health. 2018; 109(1):148-154. PMC: 6301406. DOI: 10.2105/AJPH.2018.304771. View

3.
Goyal S, Saunders K, Moore C, Fillo K, Ko J, Manning S . Identification of Substance-Exposed Newborns and Neonatal Abstinence Syndrome Using ICD-10-CM - 15 Hospitals, Massachusetts, 2017. MMWR Morb Mortal Wkly Rep. 2020; 69(29):951-955. PMC: 7377822. DOI: 10.15585/mmwr.mm6929a2. View

4.
Kroelinger C, Rice M, Cox S, Hickner H, Weber M, Romero L . State Strategies to Address Opioid Use Disorder Among Pregnant and Postpartum Women and Infants Prenatally Exposed to Substances, Including Infants with Neonatal Abstinence Syndrome. MMWR Morb Mortal Wkly Rep. 2019; 68(36):777-783. PMC: 6753967. DOI: 10.15585/mmwr.mm6836a1. View

5.
Patrick S, Faherty L, Dick A, Scott T, Dudley J, Stein B . Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome. JAMA. 2019; 321(4):385-393. PMC: 6439754. DOI: 10.1001/jama.2018.20851. View